Literature DB >> 21466476

Epigenetic mechanisms in Alzheimer's disease.

M Daniilidou1, M Koutroumani, M Tsolaki.   

Abstract

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders affecting elderly people (over 65 years old). Only a small percentage (less than 5%) of the disease is consistent with the Mendelian form of inheritance. The rest, named as Late Onset Alzheimer's Disease (more than 95%), is characterized as a complex multi-factorial disorder, missing familial traits. Although some genes have been implicated in the pathogenesis and the risk of developing sporadic AD, they only account for the minority of LOAD cases. Thus, over the past few years emerging data suggest a potential role of epigenetic mechanisms and chromatin remodeling on neurodegenerative processes leading to dementia. Alterations on the epigenomic machinery cause aberrant DNA methylation and histone acetylation. Therefore, these changes trigger alterations on the transcriptional level of genes involved in the pathogenesis of AD, such as APP. In this review we summarize recent advances on synaptic dysfunction and cognitive decline caused by common epigenetic modifications. We also discuss potential treatment strategies targeting on the epigenetic machinery.

Entities:  

Mesh:

Year:  2011        PMID: 21466476     DOI: 10.2174/092986711795496872

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

1.  Treatment with Histone Deacetylase Inhibitor Attenuates Peripheral Inflammation-Induced Cognitive Dysfunction and Microglial Activation: The Effect of SAHA as a Peripheral HDAC Inhibitor.

Authors:  Naoki Takada; Yoki Nakamura; Keisuke Ikeda; Naoki Takaoka; Kazue Hisaoka-Nakashima; Seigo Sanoh; Yaichiro Kotake; Yoshihiro Nakata; Norimitsu Morioka
Journal:  Neurochem Res       Date:  2021-06-03       Impact factor: 3.996

2.  Epigenetic drugs for Alzheimer's disease.

Authors:  Jacob Peedicayil
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

3.  Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.

Authors:  Huancun Feng; Canmao Wang; Wei He; Xinjun Wu; Shujie Li; Zhenkun Zeng; Meidan Wei; Binghong He
Journal:  Metab Brain Dis       Date:  2019-01-04       Impact factor: 3.584

4.  IRF-8 is Involved in Amyloid-β1-40 (Aβ1-40)-induced Microglial Activation: a New Implication in Alzheimer's Disease.

Authors:  Qinggan Zeng; Rongyong Man; Yifeng Luo; Ling Zeng; Yushi Zhong; Bingxun Lu; Xiaofeng Wang
Journal:  J Mol Neurosci       Date:  2017-08-31       Impact factor: 3.444

5.  Targeted proteomics for quantification of histone acetylation in Alzheimer's disease.

Authors:  Kangling Zhang; Matthew Schrag; Andrew Crofton; Rishi Trivedi; Harry Vinters; Wolff Kirsch
Journal:  Proteomics       Date:  2012-04       Impact factor: 3.984

6.  Brain site-specific proteome changes in aging-related dementia.

Authors:  Arulmani Manavalan; Manisha Mishra; Lin Feng; Siu Kwan Sze; Hiroyasu Akatsu; Klaus Heese
Journal:  Exp Mol Med       Date:  2013-09-06       Impact factor: 8.718

Review 7.  Inverse relationship between Alzheimer's disease and cancer, and other factors contributing to Alzheimer's disease: a systematic review.

Authors:  Ovais Shafi
Journal:  BMC Neurol       Date:  2016-11-22       Impact factor: 2.474

Review 8.  Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?

Authors:  Gabriela Mazzanti; Silvia Di Giacomo
Journal:  Molecules       Date:  2016-09-17       Impact factor: 4.411

9.  Transcriptomics Profiling of Alzheimer's Disease Reveal Neurovascular Defects, Altered Amyloid-β Homeostasis, and Deregulated Expression of Long Noncoding RNAs.

Authors:  Marco Magistri; Dmitry Velmeshev; Madina Makhmutova; Mohammad Ali Faghihi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 10.  Omics Approaches for Identifying Physiological Adaptations to Genome Instability in Aging.

Authors:  Diletta Edifizi; Björn Schumacher
Journal:  Int J Mol Sci       Date:  2017-11-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.